Surgery for Breast Cancer: 974 Real Stories

974 stories match breast cancer and surgery. 653 of them mention chemotherapy.

Cancer Stories

Lourdes, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Breast Cancer: Lourdes's Patient Story

Patient Info: Lourdes Monje, Under 40 | Stage IV

Metastatic Site: lung

Lourdes is receiving investigational treatment through a clinical trial, with manageable side effects, while continuing to work and spend time with family and friends.

AACR
OutcomeCare Ongoing
Lauren, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV KRAS Breast Cancer: Lauren's Patient Story

Patient Info: Lauren, Female | Stage IV

Biomarkers: KRAS mutation in colon cancer context

Metastatic Site: Abdominal lining; spine

As of September 2024, Lauren was living with a history of Stage IV colon cancer and recurrent metastatic breast cancer in the spine, with low colon tumor markers, recurring spinal spots, and PET scans every 3 months.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage 4 breast cancer: complete remission with letrozole and palbociclib

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Breast cancer was ER/PR positive, HER2 0

Metastatic Site: pleura/pleural effusion

Breast cancer remained in remission on letrozole after palbociclib was stopped; Ph-positive B-ALL achieved complete response with no molecular residual disease after blinatumomab plus ponatinib, with ongoing monthly outpatient monitoring.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Hormone receptor-positive invasive lobular carcinoma treated with neoadjuvant chemotherapy

Patient Info: Anonymized, Female, 50s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative; Ki-67 20%

Three-month follow-up showed the biopsy-related pseudoaneurysm had thrombosed and regressed, clearing the way for planned neoadjuvant chemotherapy and surgery; cancer response after planned treatment was not yet available.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage I Invasive Ductal CarcinomaBreast Cancer

Stage 1 invasive ductal breast cancer: nipple-preserving mastectomy with reconstruction

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative; Ki-67 28%

No signs of recurrence 20 months after nipple-preserving mastectomy, sentinel node biopsy, immediate reconstruction, adjuvant chemotherapy, and endocrine therapy for ER-positive, PR-positive, HER2-negative invasive ductal breast cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage 4 breast cancer: ongoing treatment with multi-line chemotherapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Initial tumor: hormone receptor-negative; HER2 2+. 2011 recurrence: ER 10%; PR 70%; HER2 2+.

Metastatic Site: pleura/pleural effusion; lung

Metastatic breast cancer with malignant pleural effusion achieved complete response after chemotherapy and long-term endocrine therapy; PET-CT in October 2023 still showed complete response, with ongoing cardiac and bone-health management.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

ER-positive breast cancer: mastectomy after hormone therapy

Patient Info: Anonymized, Female, 50s | Stage II

Biomarkers: Breast cancer was ER+ and HER2-low/negative. PR changed from positive on biopsy to negative on final pathology; HNA-1 antibody found for neutropenia.

Stage IIA ER-positive invasive ductal breast cancer had no recurrence 3 years after endocrine therapy and total mastectomy with sentinel lymph node biopsy; autoimmune neutropenia was monitored rather than directly treated.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

Triple-negative breast cancer: partial response to TAC chemotherapy

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: Triple-negative breast cancer with EGFR positivity and high Ki-67; BRCA1 staining was positive by IHC.

After 1 cycle of TAC chemotherapy, the large ulcerated breast tumor shrank enough for surgery. Radical mastectomy with adjacent flap transfer achieved clear margins and no nodal metastatic cancer; she was recovering at home while awaiting planned postoperative AC-T chemotherapy.

PubMed Central
OutcomeCare Ongoing
Kristie, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Kristie's Survivor Story

Patient Info: Kristie, Female

As of August 2024, Kristie was focused on survivorship and advocacy after extensive ILC treatment that included 20 weeks of chemotherapy, 25 radiation treatments, 2 years on Verzenio, estrogen blockers, and 5 surgeries.

Lobular Breast Cancer Alliance
OutcomeSurvivorship / Completed Treatment
Krista, who was diagnosed with Breast CancerBreast Cancer

Breast Cancer: Krista's Patient Story

Patient Info: Krista Brown, Female

Biomarkers: Pathogenic ATM mutation; hormone receptor-positive; HER2-negative; Oncotype DX score 1/100

As of August 2024, Krista had completed mastectomy/reconstruction surgery and was continuing adjuvant tamoxifen with low reported recurrence risk.

The Patient Story
OutcomeCare Ongoing
A patient, who was diagnosed with Breast CancerBreast Cancer

Triple-Negative Breast Cancer in a Family With a Rare MT1E Variant

Patient Info: Anonymized, female, 50s

Biomarkers: Triple-negative; BRCA1/2 no pathogenic variants; MT1E c. variant identified in this family

A 56-year-old woman with a strong family history of breast cancer was treated surgically for triple-negative breast cancer while genetic testing identified a rare MT1E variant in the family.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Triple-negative breast cancer: partial response to immunotherapy combination

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Initial tumor: ER-negative; PR-negative; HER2-negative; Ki-67 >80%

Metastatic Site: left lung, neck lymph nodes, mediastinal lymph nodes

Metastatic triple-negative breast cancer had a partial response after 9 months of pembrolizumab plus MK-4830, with reduced tumor burden, decreased lung and mediastinal metastases, and no new metastatic lesions; immunotherapy continued after prednisone controlled a grade 2 lichenoid eruption.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Triple-Negative Pleomorphic Lobular Breast Cancer in a BRCA1 Carrier

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative, BRCA1 pathogenic mutation

Surgery after neoadjuvant treatment showed a complete pathologic response with no cancer in the 2 sampled sentinel lymph nodes.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Right-Sided Ductal Carcinoma in Situ Before a Second Breast Cancer

Patient Info: Anonymized, female, 60s

Biomarkers: ER-positive; PR-positive; HER2 1+

A woman treated for right-sided ductal carcinoma in situ in 2018 later developed a separate invasive cancer in the opposite breast.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

HER2-Positive Breast Cancer That Spread to the Cervix

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: HER2-positive; ER and PR less than 1% in the left breast tumor

Metastatic Site: cervix, esophagus, mediastinal lymph nodes

Cervical metastasis showed a local complete response after brachytherapy, but systemic disease later progressed to the esophagus. She died after 4 months of nutritional support and palliative treatment.

PubMed Central
OutcomeIn Memory
Erica, who was diagnosed with Stage 0 Invasive Ductal CarcinomaBreast Cancer

Stage 0 DCIS breast cancer: disease-free after treatment

Patient Info: Erica, Female | Stage 0

Biomarkers: BRCA-negative

As of August 2024, Erica described herself as cancer-free after Stage 0 DCIS treated with double mastectomy and reconstruction, with peace of mind about recurrence risk.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage 3 infiltrating ductal carcinoma treated with radical mastectomy

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: Breast cancer was ER/PR positive, HER2 negative

The patient recovered fully after right radical mastectomy and complete axillary dissection for Stage III male breast infiltrating ductal carcinoma; adjuvant therapy and recurrence follow-up were not reported in the extracted case text.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage 4 invasive ductal carcinoma: metastatic disease with bone involvement managed successfully

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER <1%; PR 0%; HER2 score 3+; Ki-67 60%

Metastatic Site: bone (12th thoracic vertebra/T12)

Stage IV HER2-positive breast cancer had improved T12 bone metastasis, major breast-tumor regression on trastuzumab deruxtecan, and pathologic complete response in the breast after mastectomy; durable systemic disease status was not reported.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Breast CancerBreast Cancer

Breast cancer history with painful implant capsule: no recurrence or BIA-ALCL found

Patient Info: Anonymized, Female, 40s

Biomarkers: Implant/capsule pathology showed necrotic tissue only; no tumor cells, CD30 signal, bacteria

The painful implant/capsule episode did not show breast cancer recurrence or BIA-ALCL on pathology; symptoms and cancer concern improved after implant removal, while oral flumatinib maintenance for acute B-lymphoblastic leukemia continued.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Breast CancerBreast Cancer

Rare acinic cell breast cancer treated with mastectomy

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative; pMMR/MSS; Ki-67 very high. TP53 and several other mutations reported; no gene fusion/rearrangement found.

Alive for 43 months with no metastasis or recurrence after surgery, 8 cycles of epirubicin/cyclophosphamide, and radiotherapy for breast acinic cell carcinoma with high-grade solid transformation.

PubMed Central
OutcomeCancer-Free / NED
Jessica, who was diagnosed with Stage I Invasive Lobular CarcinomaBreast Cancer

Stage I Invasive Lobular Carcinoma: Jessica's Patient Story

Patient Info: Jessica, Female, 40s | Stage I

Biomarkers: Myriad genetic testing negative; Oncotype DX score 19; RSClin recurrence risk 19%; isolated tumor cells around 1 sentinel lymph node without invasion

As of July 2024, Jessica had completed bilateral mastectomy for Stage IB ILC and was moving forward with radiation and long-term hormone suppression after chemotherapy was not recommended.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing